Back to Browse Journals » Clinical Interventions in Aging » Volume 2 » Issue 1

Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women

Authors Esteban Jódar-Gimeno

Published 15 April 2007 Volume 2007:2(1) Pages 163—174

Esteban Jódar-Gimeno

Endocrinology and Metabolism Service, University Hospital “12 de Octubre”, Madrid, Spain. Associate Professor of Medicine Universidad Complutense, Madrid, Spain

Objective: To review the pharmacological properties and the available clinical data of full length parathyroid hormone (PTH) in post-menopausal osteoporosis.

Sources: A MEDLINE search was completed, together with a review of information obtained from the manufacturer and from the medicine regulatory agencies.

Study and data selection: Studies were selected according to relevance and availability. Relevant information (design, objectives, patients’ characteristics, outcomes, adverse events, dosing, etc) was analyzed.

Results: Different studies have shown that, when administered intermittently as a subcutaneous injection in the abdomen, PTH increases bone mineral density (BMD) and prevents vertebral fractures. On completion of PTH therapy (up to 24 months), there is evidence that sequential treatment with alendronate is associated with a therapeutic benefit in terms of increase in BMD. Further trials are necessary to determine long-term safety and the role of PTH in combination with other treatments for osteoporosis and the effect of repeated cycles of PTH followed by an anti-catabolic agent. There are currently no completed comparative trials with other osteoporosis treatments.

Conclusions: Full length PTH, given intermittently as an abdominal subcutaneous injection, appears to be a safe and efficacious treatment option for high risk osteoporosis. More data are needed to determine its specific role in osteoporosis treatment.

Keywords: postmenopausal osteoporosis, anabolic therapy, PTH (1–84)

Download Article [PDF] 

Readers of this article also read:

Impact of noncommunicable diseases in the State of Qatar

Al-Kaabi SK, Atherton A

ClinicoEconomics and Outcomes Research 2015, 7:377-385

Published Date: 2 July 2015

Oxidative stress and antibacterial properties of a graphene oxide-cystamine nanohybrid

Nanda SS, An SS, Yi DK

International Journal of Nanomedicine 2015, 10:549-556

Published Date: 12 January 2015

Review of topiramate for the treatment of epilepsy in elderly patients

BR Sommer, HH Fenn

Clinical Interventions in Aging 2010, 5:89-99

Published Date: 7 April 2010

HT update: spotlight on estradiol/norethindrone acetate combination therapy

Colleen L Casey, Christine A Murray

Clinical Interventions in Aging 2008, 3:9-16

Published Date: 7 March 2008

Update on the use of dutasteride in the management of benign prostatic hypertrophy

Joe Miller, Thomas H Tarter

Clinical Interventions in Aging 2007, 2:99-104

Published Date: 15 April 2007

Editorial: What's in a name? || Free Paper ||

Richard F Walker

Clinical Interventions in Aging 2007, 2:1-2

Published Date: 15 April 2007